(Q35601601)

9 August 2017

1 reference

title

Changing role of the oestrogen receptor in the life and death of breast cancer cells (English)

1 reference

9 August 2017

1 reference

1

V C Jordan

1 reference

9 August 2017

C Osipo

2

1 reference

9 August 2017

J MacGregor Schafer

3

1 reference

9 August 2017

J E Fox

4

1 reference

9 August 2017

Dong Cheng

5

1 reference

9 August 2017

Hong Liu

6

1 reference

9 August 2017

1 December 2003

1 reference

9 August 2017

1 reference

9 August 2017

12

1 reference

9 August 2017

6

1 reference

9 August 2017

432-441

1 reference

A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Nafoxidine--an antiestrogen for the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

A new derivative of triphenylethylene: effect on implantation and mode of action in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

New synthetic agent for the induction of ovulation: preliminary trials in women

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Antioestrogens. A review

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Tamoxifen (antiestrogen) therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Tamoxifen: a most unlikely pioneering medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Molecular basis of agonism and antagonism in the oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Response after withdrawal of tamoxifen and progestogens in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Apoptotic Action of 17 -Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2900149-8

7 January 2021

10.1016/S0960-9776(03)00149-8

Identifiers

DOI

1 reference

9 August 2017

1 reference